CZERINA OTTES: Open Payments
NPI 1780281618 · CHESTERFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$773 in 44 payments from 14 companies in 2025. Trend: 2023 $742 · 2024 $747 · 2025 $773
Food & beverage: $773
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $261 |
| Lilly USA, LLC | 5 | $122 |
| Novo Nordisk Inc | 6 | $97 |
| GlaxoSmithKline, LLC. | 3 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| PFIZER INC. | 2 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Tris Pharma Inc | 1 | $20 |
| Amgen Inc. | 1 | $20 |
Products named: UBRELVY, MOUNJARO, VRAYLAR, Ozempic, SHINGRIX, ELIQUIS, JARDIANCE, CAPLYTA.
Industry payments across MO — which companies pay providers there.
